Pfäffikon (SZ) Switzerland, 27th of July 2023: Saiba Animal Health AG announced today the execution of a new out-licensing agreement with Boehringer Ingelheim, a global leader in animal health. The new contract is the latest of several recent agreements between Saiba and Boehringer Ingelheim and further expands their collaboration base.

Commenting on the new agreement, Dr. Senta Walton, Head of Research and Development at Saiba Animal Health AG, explained: “The opportunity to out-license our latest vaccine candidate came about as a result of a promising data set generated from an initial target-species lab study and subsequent pilot field-trial in patients. The latter study we performed in collaboration with the University of Zürich Vetsuisse Faculty. Indeed, it’s an excellent example of how we’re able to leverage our scientific network and development experience to significantly advance our drugs along the development path and present an attractive package to potential partners”. Dr Walton added: “We are thrilled to build on our existing collaborations with Boehringer Ingelheim whose development expertise and commercial strength can help us fully realize the potential of our latest product candidate, one which addresses an important unmet need in veterinary medicine.”

Building on recent momentum, Saiba’s immediate business goals are fully focused on attracting capital investment to advance new projects from within its internal pipeline and implementing new agreements with strategic partners.

For additional Information, please contact
Saiba Animal Health AG
Pfäffikon (SZ)
Switzerland
Gary T. Jennings, PhD
CEO
gary.jennings@saiba-animalhealth.com
gary.jennings@usz.ch